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Objective: The race-specific association of inflammation with adiposity and muscle mass in subjects
with chronic kidney disease (CKD) was examined.
Methods: Plasma concentration of interleukin (IL)21b, IL-1 receptor antagonist (IL-1RA), IL-6, IL-10,
tumor necrosis factor (TNF)-a, TGF-b, high-sensitivity C-reactive protein (hs-CRP), fibrinogen, and serum
albumin was measured in 3,939 Chronic Renal Insufficiency Cohort study participants. Bioelectric imped-
ance analysis was used to determine body fat mass (BFM) and fat-free mass (FFM).
Results: Plasma levels of hs-CRP, fibrinogen, IL-1RA, IL-6, and TNF-a increased and serum albumin
decreased across the quartiles of body mass index. In multivariable analysis, BFM and FFM were posi-
tively associated with hs-CRP, fibrinogen, IL-1b, IL-1RA, and IL-6. One standard deviation (SD) increase
in BFM and FFM was associated with 0.36 (95% confidence interval [CI]5 0.33, 0.39) and 0.26 (95%
CI5 0.22, 0.30) SD increase in log-transformed hs-CRP, respectively (P< 0.001). Race stratified analysis
showed that the association between biomarkers and BFM and FFM differed by race, with Caucasians,
demonstrating a stronger association with markers of inflammation than African Americans.
Conclusions: BFA and FFM are positively associated with markers of inflammation in patients with CKD.
Race stratified analysis showed that Caucasians have a stronger association with markers of inflamma-
tion compared to African Americans.
Obesity (2014) 22, 1359-1366. doi:10.1002/oby.20692
Introduction
Findings from the Chronic Renal Insufficiency Cohort (CRIC) study
showed that about 86% of subjects with chronic kidney disease
(CKD) have some evidence of inflammation (1). Inflammatory state is
characterized by activation of an array of soluble factors such as cyto-
kine and chemokines. Elevated plasma cytokine levels in CKD could
be a consequence of decreased elimination and/or increased genera-
tion. It is now well recognized that obesity is a chronic inflammatory
state (2). A number of cross-sectional and longitudinal studies from
diverse populations have revealed that higher body mass index (BMI)
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is a risk factor for the prevalence and progression of CKD (3). Analy-
sis of data from the United States Renal Data System showed that
among incident patients with ESRD, mean BMI increased from 25.7
to 27.5 kg/m2 during the years 1995-2002 (4). However, BMI does not
discriminate between muscle mass and fat mass. The inflammatory
response and prognostic implications of body fat mass (BFM) and
muscle mass may be different (5). Although most of the circulating
cytokines are secreted from activated macrophages and lymphocytes,
adipocytes and skeletal muscle are also a possible source of these
cytokines (6,7). Evidence from basic science laboratory and clinical
translational studies indicate that proinflammatory cytokines mediate
muscle protein catabolism (8-11). The association between inflamma-
tion and body composition has not been studied in a large cohort of
racially diverse CKD patients with varying level of kidney function.
We hypothesized that inflammatory biomarkers are positively asso-
ciated with BFM and negatively with fat-free mass (FFM). We fur-
ther hypothesized that the association between anthropometric meas-
ures and inflammation is modulated by race. Thus, in this study, we
examine the association between inflammation and bioelectric
impedance analysis (BIA)-derived measures of adiposity and muscle
mass in CRIC study participants.
Methods
The CRIC study
The organization, design, and methods of the CRIC study have been
reported previously (12). Briefly, the CRIC study is a multicenter,
prospective observational cohort study of 3,939 subjects with estab-
lished CKD. The exclusion criteria in CRIC were monogenetic renal
disease, cirrhosis, class III or IV heart failure, HIV, cancer, autoim-
mune disease, or current immunosuppressive therapy, polycystic kid-
ney disease, pregnant women, subjects with organ or bone marrow
transplant, and persons who had received immunotherapy for pri-
mary renal disease or systemic vasculitis within the past 6 months
or had systemic chemotherapy. The study protocol was approved by
the Institutional Review Board at each participating site. Written
informed consent was obtained from all study participants.
CRIC data collection
Demographic and clinical characteristics were determined at base-
line. Self-reported race/ethnicity was documented. Serum creatinine
was measured by the Jaffe method on a Beckman Synchron System.
Serum cystatin C was measured on a Dade-Behring BNII, with a
coefficient of variation of about 1.7%. We calculated the glomerular
filtration rate using the estimating equation derived from the CRIC
cohort (eGFR) (13). BMI was calculated as body weight in kilo-
gram/(height in meters)2.
Bioelectric impedance analysis
All CRIC study participants underwent BIA studies at baseline with
a Quantum II analyzer employing standard techniques. The bioelec-
trical impedance analyzer vectors the impedance signal (Z, in ohms,
X) into resistance (R, X), and reactance (Xc, X) as a direct series
measurement. Values for FFM and BFM were determined using
established predictive formulae (14). Muscle mass was derived using
the equation that has been validated using magnetic resonance imag-
ing (15) and applied to patients with CKD (16).
FFM5 ða3Ht2Þ1 ðb3WtÞ1 ðc3AÞ1 ðd 3RÞ1 e
where Ht is height in cm, Wt is weight in kg, A is age, R is imped-
ance (X), and a and e are constants provided by the manufacturer.
BFM ðkg Þ5BW20:55 ðHt2=RÞ216:69 ðmales Þ
5BW20:55 ðHt2=RÞ211:49 ðfemales Þ
where BW is body weight in kg, Ht is height in cm.
Chertow et al. (17) have shown that BIA is a sensitive tool for eval-
uating body composition in patients with kidney disease.
Measurement of biomarkers of inflammation
High-sensitivity sandwich ELISAs (Quantikine HS, R&D Systems,
Minneapolis, MN) were used to measure plasma interleukin (IL)21b,
IL-6, and tumor necrosis factor (TNF)-a levels. Standard sandwich
ELISAs (Quantikine, R&D Systems) were used to quantify IL-1
receptor antagonist (IL-1RA) and transforming growth factor (TGF)-b
levels. Integrated performance of IL-1b, IL-1RA, IL-6, and TNF-a
ELISAs was implemented using a robotic liquid handling platform
(Biomek FXp, Beckman Coulter, Brea, CA). All cytokine assays were
performed in duplicates and the mean value was used in the analysis.
Several blood samples had a concentration of IL-1b below the mini-
mal level for detection (0.125); to these samples, we arbitrarily
assigned a very low value for IL-1b at (0.00001). High-sensitivity C-
reactive protein (hs-CRP) and fibrinogen were quantified in EDTA
plasma samples using specific laser-based immunonephelometric
methods on the BNII (Siemens Healthcare Diagnostics, Deerfield, IL).
Calculation of inflammation score
We computed a composite score ranging from 0 to 5 based on the
levels as reported by us earlier (1). When the levels of the following
biomarkers were at or above the range indicated a score of “1” was
assigned: (a) hs-CRP> 3 mg/l, (b) fibrinogen> 350 mg/dl, (c) IL-
6 6 pg/ml, (d) TNF-a 7 pg/ml, and (e) IL-1b 0.39 pg/ml. The
cut-off values for individual biomarkers were chosen from the previ-
ously published literature.
Statistical analysis
Selected demographic and clinical characteristics of the study popula-
tion were summarized by BMI quartiles. Continuous variables were
presented as mean and standard deviation (SD), or median and inter-
quartile range, and were compared across BMI quartiles using
ANOVA or Kruskal-Wallis test, as appropriate. Categorical variables
were presented as frequency and percentages and were compared
across BMI quartiles using a v2-test. Multivariable linear regression
models were employed to estimate the association of BMI, BFM, and
FFM with biomarkers of inflammation, adjusting for age, sex, clinical
center, diabetes, hypertension, smoking, total cholesterol, lipid-
lowering medications, aspirin and ACE-I/ARB use, metabolic equiva-
lent of tasks (METSs), and eGFR, which was estimated using an equa-
tion developed within CRIC (13). Natural logarithm transformation
(ln) was applied to the biomarkers of inflammation that had skewed
distribution. In the regression analyses done in each instance, adjust-
ment was made only for one cytokine or inflammatory marker in each
model tested. Both the exposures (i.e., BMI, BFM, and FFM) and
outcomes of interest were standardized by dividing the SDs. An
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additional subgroup analysis estimated the association of BMI, BFM,
and FFM with biomarkers of inflammation by eGFR group, dividing
the CRIC participants into two groups: (1) individuals with advanced
CKD with an eGFR of< 30 ml/min/1.73 m2 (n5 804) and individuals
with an eGFR of 30 ml/min/1.73 m2 (n5 3,123). We dichotomized
the cohort because the number of subjects in each stage of CKD was
too small to derive meaningful conclusions. The analysis was adjusted
for age, sex, clinical center, diabetes, hypertension, smoking, total
cholesterol, lipid-lowering medications, aspirin and ACE-I/ARB use,
METS, and eGFR. Subgroup analyses were done in Caucasian and
African Americans and formal tests of effect modification by race
were done by checking the significance of the interaction terms
between race and biomarkers of inflammation. We also investigated
the interaction between race and biomarkers of inflammation by
eGFR level (eGFR, <30 ml/min/1.73 m2; eGFR, 30 ml/min/1.73
m2). Subgroup analysis was not done in Hispanics because of the rela-
tively small sample size. All analyses were done with the SAS statisti-
cal software (V9.3, SAS Inc., Cary, NC).
Results
We studied 3,684 out of the 3,939 (93.5%) CRIC study participants,
in whom BIA and inflammation biomarker results were available.
TABLE 1 Demography of the study population according to the quartiles of BMI
Variable
BMI (kg/m2)
P-value
<26.8
(n5915)
26.8 to <30.9
(n5 920)
30.9 to <36.1
(n5928)
36.1
(n5 921)
Age (years) 56.7 (12.3) 59.2 (10.9) 59.2 (10.2) 57.5 (10.4) <0.01
Male (%) 479 (52.4) 614 (66.7) 556 (59.9) 360 (39.1) <0.01
Race/ethnicity (%)
Caucasians 459 (50.2) 411 (44.7) 377 (40.6) 319 (34.6) <0.01
African Americans 290 (31.7) 343 (37.3) 402 (43.3) 492 (53.4)
Hispanics 103 (11.3) 119 (12.9) 128 (13.8) 91 (9.9)
Othera 63 (6.9) 47 (5.1) 21 (2.3) 19 (2.1)
Diabetes (%) 288 (31.5) 400 (43.5) 480 (51.7) 600 (65.2) <0.01
Hypertension (%) 710 (77.6%) 796 (86.5%) 811 (87.4%) 851 (92.4%) <0.01
Smokers (%) 167 (18.3) 120 (13.0) 105 (11.3) 88 (9.6) <0.01
Educational level (%)
College graduate 370 (40.4) 325 (35.4) 278 (30.0) 200 (21.7) <0.01
Some college education 223 (24.4) 265 (28.8) 286 (30.8) 299 (32.5)
Higher secondary graduation 147 (16.1) 155 (16.9) 164 (17.7) 218 (23.7)
Less than higher secondary education 175 (19.1) 174 (18.9) 200 (21.6) 204 (22.2)
Calorie intake (kcal/kg/day) 26.0 (11.5) 21.7 (9.5) 19.2 (8.4) 16.4 (7.6) <0.01
Protein intake (g/kg/day) 1.0 (0.5) 0.8 (0.4) 0.8 (0.4) 0.6 (0.3) <0.01
Total METS (kcal/kg/h) 168 (116-254) 170 (112-256) 167 (109-245) 153 (104-242) 0.03
HOMA-IR 4.1 (5.5) 5.9 (7.4) 6.9 (7.6) 9.1 (9.4) <0.01
Hemoglobin (g/dl) 12.6 (1.8) 12.9 (1.8) 12.7 (1.7) 12.3 (1.7) <0.01
WBC count (3103/ml) 6.3 (2.0) 6.4 (1.9) 6.6 (2.0) 7.0 (3.0) <0.01
Serum creatinine (mg/dl) 1.72 (0.60) 1.75 (0.57) 1.75 (0.57) 1.73 (0.56) 0.72
CRIC eGFR (ml/min/1.73 m2) 46.8 (18.3) 46.2 (16.4) 45.4 (16.8) 41.9 (15.2) <0.01
Cystatin C (mg/l) 1.45 (0.54) 1.46 (0.52) 1.50 (0.54) 1.62 (0.53) <0.01
Total cholesterol (mg/dl) 187.1 (45.5) 184.3 (46.4) 183.1 (46.1) 181.9 (43.0) 0.08
Low-density lipoprotein (mg/dl) 103.9 (35.0) 103.8 (36.4) 101.5 (35.0) 102.2 (34.7) 0.37
Triglyceride (mg/dl) 130.8 (90.0) 160.3 (117.6) 170.7 (131.1) 166.7 (118.4) <0.01
Body composition
BFM (kg) 18.0 (5.8) 25.2 (6.5) 32.3 (7.8) 48.4 (14.5) <0.01
FFM (kg) 49.6 (10.2) 58.8 (11.3) 63.5 (14.0) 70.2 (17.5) <0.01
FFM/BFM 3.4 (3.9) 2.7 (2.8) 2.6 (9.8) 1.8 (2.6) <0.01
Waist circumference (cm) 87.5 (9.3) 100.2 (8.1) 109.7 (10.2) 126.1 (13.7) <0.01
Lipid-lowering drugs (%) 446 (49.2) 554 (60.8) 582 (62.9) 604 (66.1) <0.01
Data presented as mean and SD or median and interquartile range.
Abbreviations: HS, high school; METS, metabolic equivalent of tasks; HOMA-IR, homeostasis model of assessment-insulin resistance.
aAsian/Pacific Islanders and Native Americans.
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Baseline clinical and demographic characteristics according to the
quartile of BMI are summarized in Table 1. Subjects in the highest
quartile were more likely to be African American, females with
hypertension, insulin resistance, and diabetes, who were physically
inactive and received treatment with lipid-lowering agents. They
also had the lowest hemoglobin level and highest WBC count. Indi-
viduals in the lowest BMI group were more likely to be Caucasian,
smokers, with a college level education, who consumed the highest
amount of protein and calories. Although serum creatinine was not
significantly different across the quartiles of BMI, eGFR was lower
and cystatin C level was greater in patients in the highest quartile of
BMI. As expected, waist circumference, BFM, and FFM were
higher in the larger BMI groups. The ratio of FFM to BFM
decreased across the higher BMI categories.
Plasma levels of hs-CRP, fibrinogen, IL-1RA, IL-6, and TNF-a
increased significantly across increasing quartiles of BMI (Table 2.
Serum albumin, on the other hand, decreased significantly in the
higher BMI group. There were 531 (14.4%) subjects with no evi-
dence of inflammation (inflammation score, “0”) and 173 subjects
(4.7%) with inflammation score of 4. As shown in Figure 1, sub-
jects with a higher inflammation score tend to have larger BMI, as
well as higher BFM and FFM (P< 0.01). Subjects with inflamma-
tion score of 4 had a significantly higher BMI (34.26 7.9 vs.
28.56 5.4 kg/m2, P< 0.001), BFM (33.56 16.2 vs. 24.86 9.8 kg,
P< 0.001), and FFM (63.06 16.1 vs. 59.66 15.5 kg, P5 0.02)
compared to those with inflammation score of “0”.
In multivariable linear regression, after adjusting for age, sex, clini-
cal center, diabetes, hypertension, smoking, total cholesterol, lipid-
lowering medications, ACE-I/ARB, METS, aspirin use, and eGFR,
BMI was positively associated with IL-1b, IL-1RA, IL-6, hs-CRP,
and fibrinogen, but negatively with serum albumin (Table 3). Simi-
lar association between the biomarkers of inflammation with BFM
and FFM was noted, except that the association between serum albu-
min and BFM was not significant. One SD increase in BFM and
FFM was associated with a 0.36 (95% confidence interval
[CI]5 0.33, 0.39) and a 0.26 (95% CI5 0.22, 0.30) unit increase in
ln hs-CRP, respectively (P< 0.001 for both). FFM was weakly, but
negatively associated with TNF-a and serum albumin. We examined
whether the association between body composition and inflammation
differs in patients with eGFR< 30 ml/min/1.73 m2 and 30 ml/min/
1.73 m2 (Table 4). Positive association between BFM, FFM, and IL-
1b, FFM and IL-10, as well as negative association between TNF-a
and FFM noted in those with higher eGFR did not retain signifi-
cance in subjects with lower eGFR.
While examining the association between body composition and
inflammation, significant interaction with race was evident. Interac-
tion between race and BFM was noted for IL-6 (P5 0.03), IL-1RA
(P5 0.004), and the inflammation score (P5 0.003) in the full cohort
(Figure 2). On subgroup analysis, such interaction was evident only in
TABLE 2 Biomarkers of inflammation according to the quartiles of BMI
BMI (kg/m2)
Variable <26.8 (n5915) 26.8 to <30.9 (n5 920) 30.9 to <36.1 (n5 928) 36.1 (n5 921) P-value
Acute-phase proteins
hs-CRP (mg/l) 1.2 (0.6-3.2) 2.0 (0.9-5.0) 2.9 (1.3-6.6) 4.7 (2.1-9.1) <0.01
Fibrinogen (mg/l) 3,700 (3,100-4,400) 3,900 (3,300-4,600) 4,100 (3,400-4,800) 4,500 (3,800-5,200) <0.01
Albumin (g/dl)a 3.99 (0.51) 3.97 (0.46) 3.96 (0.45) 3.85 (0.43) <0.01
Cytokines
IL-1b (pg/ml) 0.18 (0.06-1.1) 0.18 (0.06-1.1) 0.15 (0.06-1.3) 0.3 (0.06-1.4) 0.08
IL-1RA (pg/ml) 503 (291-1,177) 637 (358-1,346) 692 (419-1,471) 1,086 (575-1,909) <0.01
IL-6 (pg/ml) 1.4 (0.9-2.4) 1.7 (1.0-3.0) 2.0 (1.2-3.1) 2.4 (1.6-3.7) <0.01
IL-10 (>0 pg/ml)b 148 (16.3%) 132 (14.4%) 155 (16.8%) 148 (16.1%) 0.5
TNF-a (pg/ml) 2.1 (1.4-3.2) 2.1 (1.5-3.2) 2.2 (1.5-3.3) 2.3 (1.7-3.3) 0.006
TGF-b (pg/ml) 10.3 (6.1-17.7) 11.5 (6.4-18.4) 10.7 (6.2-17.5) 11.0 (7.1-17.8) 0.3
Data presented as median and interquartile range.
aMean (SD).
bn (%) where IL-10 is >0.
Figure 1 Association between inflammation score and BMI, BFM, and FFM in CRIC
study participants. All anthropometric measures were higher in CRIC study partici-
pants with higher inflammation score (P< 0.01).
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subjects with only in those with eGFR 30 ml/min/1.73 m2
(n5 3,123) and confined to the inflammation score (P5 0.015) and
IL-1RA (P5 0.023; data not shown). Interaction was significant for
IL-1RA (P5 0.045) for FFM in the full cohort (Figure 3). On further
analysis, such interaction was confined to those with eGFR< 30 ml/
min/1.73 m2 (n5 804) for fibrinogen, TGF-b, and IL-1b (P-values of
0.04, 0.006, and 0.039, respectively; data not shown). These associa-
tions were stronger in Caucasians compared to African Americans.
Discussion
In this study, we examined the association between body composi-
tion determined by BIA and biomarkers of inflammation in a large,
cohort of subjects with a broad range of kidney function. In general,
a robust positive association between BFM and several proinflam-
matory biomarkers was evident. However, contrary to our hypothe-
sis, a positive association between FFM and some inflammatory
markers was noted. Race stratified analysis showed that the associa-
tion between inflammatory biomarkers and body composition differs
by race, with Caucasians demonstrating a stronger association with
markers of inflammation as compared to African Americans.
BMI is a simple index to classify adults as overweight or obese
(18). We found that about 84.2% of the CRIC study participants
were either overweight or obese, with 55.6% being obese. Not unex-
pectedly, we noted higher representation of African American
females in the larger BMI category (Table 1). Obesity among Afri-
can Americans has been variously attributed to genetics, weight mis-
perception, and lower socioeconomic status. Several cross-sectional
and longitudinal studies have shown that higher BMI is associated
with prevalent CKD and a risk factor for the progression of CKD
(3,19). Accordingly, we found that eGFR was lower and cystatin C
higher across increasing quartiles of BMI (P< 0.01). Cystatin C is
claimed to be a more sensitive marker for kidney function than
serum creatinine (20), and it has also greater association with
inflammation (1). Reanalysis of the data using the traditional defini-
tion of obesity by BMI (21) did not change any of the observations
except that those with BMI< 18.5 and 35 had higher level of
TNF-a compared to others. However, there were only 23 subjects in
the BMI< 18.5 category.
We found that the plasma level of proinflammatory cytokines (IL-6
and TNF-a) and positive acute-phase proteins (hs-CRP and fibrino-
gen) increased across the quartiles of BMI (Table 2). Although the
IL-1b level was not different, the plasma level of IL-1RA was sig-
nificantly higher in subjects with larger BMI. Circulating cytokine
receptors may provide additional information in chronic inflamma-
tory conditions because they generally have a longer half-life than
the cytokines themselves, and therefore exhibit more constant levels
over time (22).
There is mounting evidence to suggest that BMI may not be an ideal
measure of obesity as it does not discriminate between fat mass and
muscle mass (21). BIA determines electrical impedance of body tis-
sues from which BFM and FFM can be reliably estimated in sub-
jects with and without kidney disease (14,17,23). Contribution of
adipose tissue and skeletal muscle mass to the prevailing inflamma-
tory state and clinical outcomes may be different (24). In response
to inflammatory signals, adipocytes induce the expression of several
mediators of inflammation (25). Adipocytokines, through autocrine,
paracrine, and endocrine mechanisms, mediate changes in body
composition (5). To clearly chart the association between inflamma-
tion and body composition, it is important to integrate information
derived from multiple biomarkers as a measure of prevailing inflam-
matory state (1). We computed an inflammation score using multiple
proinflammatory markers and found that the BMI, BFM, and FFM
increased progressively and significantly with a higher intensity of
inflammation (Figure 1).
In multivariable linear regression after adjusting for confounding
variables, a positive association between several markers of inflam-
mation and body composition was evident (Table 3). The association
between inflammatory biomarkers and BFM and FFM was
TABLE 3 Multivariable-adjusted association between body composition and biomarkers of inflammation
Predictor variable
BMI BFM FFM
Outcome variable Est/1 SD(95% CI) P-value Est/1 SD (95% CI) P-value Est/1 SD (95% CI) P-value
Acute-phase proteins
ln(hs-CRP1 1)/1 SD 0.34 (0.31, 0.37) <0.001 0.36 (0.33, 0.39) <0.001 0.26 (0.22, 0.30) <0.001
Fibrinogen/1 SD 0.20 (0.17, 0.23) <0.001 0.18 (0.15, 0.21) <0.001 0.17 (0.14, 0.21) <0.001
Serum albumin/1 SD 20.07 (20.10, 20.04) <0.001 0.02 (20.01, 0.06) 0.2 20.15 (20.19, 20.11) <0.001
Cytokines
ln (IL-1b1 1)/1 SD 0.05 (0.02, 0.08) 0.002 0.04 (0.01, 0.07) 0.02 0.05 (0.01, 0.09) 0.02
ln (IL-1RA1 1)/1 SD 0.20 (0.17, 0.24) <0.001 0.22 (0.19, 0.25) <0.001 0.16 (0.12, 0.20) <0.001
ln (IL-61 1)/1 SD 0.15 (0.12, 0.18) <0.001 0.14 (0.11, 0.18) <0.001 0.13 (0.09, 0.17) <0.001
ln (IL-101 1)/1 SD 20.00 (20.04, 0.03) 0.8 20.01 (20.05, 0.02) 0.5 0.03 (20.01, 0.07) 0.2
ln (TGF-b1 1)/1 SD 0.00 (20.03, 0.04) 0.8 0.01 (20.02, 0.05) 0.4 20.03 (20.07, 0.01) 0.1
ln (TNF-a1 1)/1 SD 20.01 (20.04, 0.02) 0.6 20.01 (20.04, 0.02) 0.6 20.04 (20.08, 20.01) 0.03
Adjusted for age, sex, clinical center, diabetes, hypertension, smoking, total cholesterol, lipid-lowering medications, aspirin and ACE-I/ARB use, METS, and estimated
GFR.
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influenced by the level of eGFR (Table 4). These findings should be
interpreted with caution as the number of patients with eGFR< 30
ml/min/1.73 m2 was small. The relative contribution of adipocyto-
kines released from adipocytes and myokines from skeletal muscle
to the systemic inflammation is not known (10,24). Preliminary evi-
dence indicates that skeletal muscle and adipose tissue contribute to
about 12% and 10-35% of the circulating IL-6, respectively (11).
Using arteriovenous balance studies and immunohistochemistry tech-
niques, we showed that skeletal muscle is an important source of
cytokines in patients with ESRD (7,10). When secreted from the
muscle, IL-6 acts as a hormone, signaling and affecting the liver
and adipose tissue. Besides its well-recognized role in mediating
muscle protein catabolism, cytokines are also essential for successful
muscle regeneration (10,26). In this study, we noted that one SD
increase in BFM and FFM was associated with 0.14 SD (95%
CI5 [0.11, 0.18]) and 0.13 SD (95% CI5 [0.09, 0.17]) SD increase
in ln(IL-6), respectively (Table 3). Surprisingly, we noted a weak
but negative association between serum albumin and FFM. Raj et al.
(10,27) studied protein kinetics in patients with kidney disease using
a three-compartmental model and showed that IL-6 mediates muscle
protein breakdown, and the amino acid released from muscle is uti-
lized for acute-phase protein synthesis in the liver. However, the dif-
ferential role for adipocytokines and myokines on albumin kinetics
needs further investigation using techniques that determine muscle
mass more precisely.
In a large prospective cohort study that examined the association
between BMI and death rates among US adults, mortality rates
increased with higher BMI, but less so for African Americans (28).
In our study, we observed that the association between adiposity and
inflammation is modified by race. The associations were more robust
in Caucasians than in African Americans (Figure 2). African Ameri-
cans have less visceral fat compared to Caucasians with similar waist
to hip ratio and BMI (29,30). This may explain the lower degree of
inflammation present in African Americans as visceral fat is known
to have higher expression of proinflammatory cytokines such as
TNF-a and IL-6 (31). The amount of FFM also differs between eth-
nicities. African Americans have more FFM compared to Caucasians,
which may also contribute to the racial differences observed between
these ethnicities (32). The attenuated inflammatory signals from fat
mass may explain in part the improved survival reported in obese
members of the racial minority groups with kidney disease.
Our study has number of strengths, which includes a large cohort of
patients with representation of different races, broad range of kidney
function, study of a number of biomarkers, and determination of body
composition using BIA. However, our findings should be considered
within the context of several limitations: (a) this is a cross-sectional
study and hence temporal associations and causality cannot be
inferred; (b) cytokine profile and acute-phase response exhibit inter-
and intraindividual variability over time (33); (c) the determination of
body composition by BIA could be influenced by changes in hydra-
tion (34); and (d) BIA does not distinguish between visceral and sub-
cutaneous adiposity. It has been shown that visceral fat is a stronger
predictor of inflammation than fat deposits in other sites (35).
Conclusions
To summarize, we examined the association of adiposity and muscle
mass with biomarkers of inflammation in CRIC study participants
and noted a strong positive association between several markers of
inflammation and BFM. The association between FFM and inflam-
matory biomarkers was also positive in general, but less pronounced.
Race stratified analysis showed that the association between adipos-
ity and inflammation was stronger in Caucasians compared to Afri-
can Americans. Additional studies aimed toward understanding the
genetic and molecular mechanisms for the racial differences in
inflammatory response to adiposity are warranted.O
VC 2014 The Obesity Society
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